Gastrojejunostomy as an Evolving Therapeutic Paradigm in the Management of Metastatic Pancreatic Tumors: A Comprehensive Case Review Illuminating the Strategic Role of Gastrointestinal Anastomosis
Main Article Content
Abstract
In the intricate landscape of metastatic pancreatic tumors, the therapeutic approach continues to evolve, with a burgeoning emphasis on innovative strategies to enhance patient outcomes. This comprehensive case review delves into the nuanced realm of gastrojejunostomy as a pivotal intervention in the management of metastatic pancreatic tumors. The case under scrutiny presents a compelling narrative of a patient grappling with the formidable challenge of pancreatic malignancy, wherein the judicious application of gastrojejunostomy emerged as a strategic maneuver to navigate the complexities of gastrointestinal obstruction.
Our analysis unfolds the intricate details of the patient's clinical journey, exploring the diagnostic intricacies, treatment modalities, and the ultimate decision-making process leading to the implementation of gastrojejunostomy. The discussion encapsulates the anatomical and physiological considerations inherent to this procedure, delineating its role in mitigating symptoms, improving nutritional status, and fostering an enhanced quality of life for the afflicted individual.
Furthermore, we illuminate the broader implications of gastrojejunostomy within the context of multidisciplinary care, underscoring its integration into the evolving landscape of therapeutic options for metastatic pancreatic tumors. This case review endeavors to contribute valuable insights into the clinical decision-making matrix, providing clinicians with a nuanced understanding of the role and potential benefits of gastrojejunostomy in the comprehensive management of patients with metastatic pancreatic malignancies. As the medical community continues to unravel the intricacies of gastrointestinal anastomosis, this exploration serves as a testament to the evolving armamentarium available to confront the challenges posed by metastatic pancreatic tumors, ultimately fostering a more informed and effective approach to patient care.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654
II. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi: 10.1158/0008-5472.CAN-14-0155
III. Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817–1825. doi: 10.1056/NEJMoa1011923
IV. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):16911703.doi:10.1056/NEJMoa1304369
V. Conroy T, Hammel P, Hebbar M, et al.; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018; 379(25):2395–2406.
doi: 10.1056/NEJMoa1809775
VI. Pancreatic Adenocarcinoma, Version 1.2020. National Comprehensive Cancer Network; 2019.
VII. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–427. doi: 10.1001/jamaoncol.2020.7328
VIII. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi: 10.1056/NEJMoa1903387